{
    "N/R/U": null,
    "Applicant": "Takeda Pharmaceuticals U.S.A., Inc.",
    "BLA Number": "761090",
    "Proprietary Name": "Takhzyro",
    "Proper Name": "lanadelumab-flyo",
    "BLA Type": "351(a)",
    "Strength": "300MG/2ML (150MG/ML)",
    "Dosage Form": "Injection ",
    "Route of Administration": "Subcutaneous",
    "Product Presentation": "Pre-Filled Syringe",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "February 08, 2022",
    "Ref. Product Proper Name": null,
    "Ref. Product Proprietary Name": null,
    "Supplement Number": "3",
    "Submission Type": "Supplement",
    "License Number": "1898",
    "Product Number": "002",
    "Center": "CDER",
    "Date of First Licensure": null,
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": null,
    "Ref. Product Exclusivity Exp. Date": null,
    "Orphan Exclusivity Exp. Date": "February 03, 2030"
}